Press release
Persistent Epithelial Defects Pipeline Insight 2025: Regenerative Biologics, Novel Growth Factor Therapies, and Advanced Ocular Surface Modulators Drive Innovation | DelveInsight
Persistent Epithelial Defects Pipeline Insight
DelveInsight's "Persistent Epithelial Defects - Pipeline Insight, 2025 [https://www.delveinsight.com/report-store/persistent-corneal-epithelial-defects-pceds-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]" highlights an emerging wave of candidates designed to enhance corneal healing and prevent complications. Recombinant growth factors such as nerve growth factor (NGF) and epidermal growth factor (EGF) are being evaluated for their ability to stimulate epithelial proliferation and migration. Cell- and tissue-based approaches, including cultivated limbal epithelial transplantation and engineered amniotic membrane products, are advancing in clinical studies, offering regenerative potential for patients unresponsive to conventional therapy. Novel ocular surface modulators-ranging from integrin antagonists to matrix protein enhancers-are being investigated to optimize corneal adhesion, reduce inflammation, and accelerate wound closure.
The 2025 pipeline for PEDs reflects a paradigm shift toward biologics, regenerative medicine, and precision-targeted therapeutics. With regulatory pathways encouraging innovation in rare ophthalmic disorders and increasing industry-academic collaborations, these next-generation therapies hold promise to transform outcomes for patients with persistent epithelial defects-moving beyond supportive care toward definitive, vision-preserving solutions.
Interested in learning more about the current treatment landscape and the key drivers shaping the persistent epithelial defects pipeline? Click here [https://www.delveinsight.com/report-store/persistent-corneal-epithelial-defects-pceds-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]
Key Takeaways from the Persistent Epithelial Defects Pipeline Report
- DelveInsight's persistent epithelial defects pipeline analysis depicts a strong space with 5+ active players working to develop 5+ pipeline drugs for persistent epithelial defects treatment.
- The leading persistent epithelial defects companies include Eyevance/Amber Ophthalmics, Kala Pharmaceuticals, Noveome Biotherapeutics, Oyster Point Pharma, and others are evaluating their lead assets to improve the persistent epithelial defects treatment landscape.
- Key persistent epithelial defects pipeline therapies in various stages of development include Nexagon, KPI-012, ST266, OC-01, and others.
- In July 2025, Kala Bio announced completion of enrollment in its Phase 2b "CHASE" trial evaluating KPI-012, a human mesenchymal stem cell secretome, for treating PCED. The multicenter, randomized, double-masked, vehicle-controlled trial enrolled 79 patients across 37 sites in the U.S. and Latin America, with the goal of assessing complete healing of PCED as the primary endpoint
Persistent Epithelial Defects Overview
Persistent Epithelial Defects (PEDs) refer to areas of the corneal epithelium that fail to heal within the expected timeframe, typically persisting for more than 2 weeks despite standard medical treatment. These defects are often secondary to underlying conditions that disrupt normal epithelial healing, such as neurotrophic keratopathy, limbal stem cell deficiency, exposure keratopathy, severe dry eye disease, or mechanical trauma. PEDs can lead to complications like stromal melting, infection, and scarring, posing a threat to vision.
Management of PEDs involves addressing the underlying cause, promoting re-epithelialization, and protecting the ocular surface. Treatment strategies may include aggressive lubrication, bandage contact lenses, punctal occlusion, amniotic membrane transplantation, autologous serum eye drops, and newer biologics such as cenegermin (recombinant human nerve growth factor). In refractory cases, surgical intervention may be necessary. Early diagnosis and tailored treatment are critical to prevent long-term visual impairment.
Find out more about persistent epithelial defects medication at https://www.delveinsight.com/report-store/persistent-corneal-epithelial-defects-pceds-pipeline-insight [https://www.delveinsight.com/report-store/persistent-corneal-epithelial-defects-pceds-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]
Persistent Epithelial Defects Treatment Analysis: Drug Profile
KPI-012: Kala Pharmaceuticals
Kala Pharmaceuticals is developing KPI-012, a novel biologic therapy in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare condition characterized by impaired corneal healing. KPI-012, currently in a Phase II clinical trial expected to complete in February 2024, is being evaluated not only for PCED but also for potential expansion into other rare front-of-eye diseases, including partial limbal stem cell deficiency and moderate-to-severe Sjogren's syndrome. KPI-012 is derived from a proprietary mesenchymal stem cell secretome (MSC-S) platform, which Kala acquired through its November 2021 acquisition of Combangio, Inc. The company is focused on harnessing this MSC-S technology to develop regenerative biologic therapies for ocular surface diseases.
Nexagon: Eyevance/Amber Ophthalmics
Nexagon (lufepirsen ophthalmic gel) is a first-in-class, unmodified antisense oligodeoxynucleotide developed by Amber Ophthalmics (formerly Eyevance), targeting connexin43 (Cx43), a cell membrane protein that becomes overexpressed following acute injury or in chronic disease. Overexpression of Cx43 leads to dysfunctional hemichannel activity, resulting in the release of extracellular ATP and activation of the inflammasome pathway, which drives inflammation, microvascular damage, and limbal ischemia. By inhibiting Cx43, Nexagon interrupts this inflammatory cascade, restores limbal microvasculature, and supports corneal epithelial regeneration. Nexagon demonstrated positive Phase II results in PCED secondary to chemical or thermal injury and has been granted orphan drug status by the FDA. Amber Ophthalmics plans to initiate a Phase II/III trial in a broader PCED population in Q1 2023.
Learn more about the novel and emerging persistent epithelial defects pipeline therapies [https://www.delveinsight.com/report-store/persistent-corneal-epithelial-defects-pceds-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr].
Persistent Epithelial Defects Therapeutics Assessment
By Product Type
- Mono
- Combination
- Mono/Combination.
By Stage
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
By Route of Administration
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
By Molecule Type
- Oligonucleotide
- Peptide
- Small molecule
Scope of the Persistent Epithelial Defects Pipeline Report
- Coverage: Global
- Key Persistent Epithelial Defects Companies: Eyevance/Amber Ophthalmics, Kala Pharmaceuticals, Noveome Biotherapeutics, Oyster Point Pharma, and others.
- Key Persistent Epithelial Defects Pipeline Therapies: Nexagon, KPI-012, ST266, OC-01, and others.
Explore detailed insights on drugs used in the treatment of persistent epithelial defects here [https://www.delveinsight.com/report-store/persistent-corneal-epithelial-defects-pceds-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr].
Table of Contents
1. Introduction
2. Executive Summary
3. Persistent Epithelial Defects Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Persistent Epithelial Defects Pipeline Therapeutics
6. Persistent Epithelial Defects Pipeline: Late-Stage Products (Phase III)
7. Persistent Epithelial Defects Pipeline: Mid-Stage Products (Phase II)
8. Persistent Epithelial Defects Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Jatin Vimal
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=persistent-epithelial-defects-pipeline-insight-2025-regenerative-biologics-novel-growth-factor-therapies-and-advanced-ocular-surface-modulators-drive-innovation-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Persistent Epithelial Defects Pipeline Insight 2025: Regenerative Biologics, Novel Growth Factor Therapies, and Advanced Ocular Surface Modulators Drive Innovation | DelveInsight here
News-ID: 4152131 • Views: …
More Releases from ABNewswire
Kiwifruit Powder: More Than Just Dried Fruit Powder, Unlock Natural Nutrition
When it comes to kiwifruit, they often associate it with its sweet, sour, and juicy taste and its reputation as the "King of Vitamin C." But did you know that converting fresh kiwifruit into kiwi Fruit Powder [https://www.risunextract.com/fruit-powder-1/] not only overcomes the storage and transportation limitations of fresh fruit, but also significantly upgrades its nutritional value and applications? What hidden nutritional advantages and practical value does this seemingly simple "dried…
Nitroxoline Production Method: An Overview - Industry Trends and Best Practices
Nitroxoline, a synthetic compound belonging to the class of 8-hydroxyquinolines, has garnered attention for its potential applications in the medical field, particularly as an antimicrobial agent. The production method of nitroxoline is crucial for ensuring its efficacy and purity, which are essential for its therapeutic use.
The primary method for producing nitroxoline involves the condensation of 8-hydroxyquinoline with a suitable alkylating agent. This process typically begins with the synthesis of 8-hydroxyquinoline,…
Nitroxoline: Key Uses and Applications in Medicine
Nitroxoline: Key Uses and Applications in Medicine
Nitroxoline, a synthetic compound belonging to the class of 8-hydroxyquinolines, has garnered attention in the medical field due to its diverse applications. Originally developed as an antimicrobial agent, nitroxoline has proven effective against a range of bacterial infections, particularly those affecting the urinary tract. Its ability to inhibit bacterial growth makes it a valuable option for treating conditions such as cystitis and pyelonephritis.
One of…
Consumer Focus, Everyday Uses & Environmental Angle
We've all tossed them aside - those small, crinkly packets marked "DO NOT EAT" filled with tiny blue beads, found in everything from new purses to gadget boxes. But blue silica gel is more than just packaging filler; it's a powerful, reusable tool hiding in plain sight. Understanding what it is, how it truly works, and its responsible use can save money, protect belongings, and even reduce waste. However, its…
More Releases for Persistent
Evolving Market Trends In The Advanced Persistent Threat Protection Industry: In …
The Advanced Persistent Threat Protection Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Advanced Persistent Threat Protection Market Size During the Forecast Period?
The market size for advanced persistent threat protection has seen a substantial increase in the recent past. It is…
Advanced Persistent Threat Protection Market Size and Forecast
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Advanced Persistent Threat Protection Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion.
The Advanced Persistent Threat (APT) Protection market is experiencing significant growth due to the increasing frequency and sophistication of cyberattacks. APTs are long-term,…
Decentralized Identity Systems Market Dynamics and Demand A Deep Dive into Trend …
The Decentralized Identity Systems Market is an emerging and transformative sector within the blockchain and digital identity industries, offering a secure and user-centric approach to managing identity information. Decentralized identity systems empower individuals to have more control over their personal data and digital identities, reducing reliance on centralized entities for identity verification. These systems utilize blockchain technology and cryptography to provide secure, privacy-enhancing, and interoperable solutions for identity management. As…
Global Advanced Persistent Threat Protection Market
The data examined by GME predicted that by 2026, the Global Advanced Persistent Threat Protection Market would grow with a CAGR value of 19.5 percent. External threats are constantly on the lookout for opportunities to hack security networks and obtain access to sensitive data. Hence, with the rising cases of cyber security thefts or crime will help propel the market from 2021 to 2026. Moreover the market is projected to…
Pyrometer Market Expansion to be Persistent During 2028
Pyrometer Market – Notable Developments
In April 2019, AMETEK Land revealed its enhanced SPOT infrared pyrometer software packages, SPOTPro and SPOTViewer. The newly launched pyrometer packages are aimed at giving users a better understand of the performance of various processes and aid them in realizing industry 4.0 connectivity.
In December 2018, Extech announced launch of a ruggedized, dual-laser infrared (IR) thermometer named IR320, which is designed to perform rough and tough jobs…
DevSecOps Market Expansion to be Persistent during 2023
Overview:
In the recent times, a new trend is gaining popularity in the software development life cycle called DevSecOps. This technology bridges the gap between development, operations, and security teams to speed up the software development process through collaboration and communication among the teams. The goal of DevOps is to give more ownership to the development team for developing and monitoring applications. Security plays a key role by providing high-end security…
